The company expects EPS to be between $4.02 and $4.12. On a non-GAAP basis, EPS is expected to be in the range of $4.75 and $4.85.
Within diagnostics, Beckman Coulter saw core revenue growth in the low-single digits, while Cepheid was up in the double digits for the quarter.
The test detects and quantifies hepatitis C virus RNA and can be performed in approximately one hour.
Testing with Cepheid's molecular TB assay can shorten the amount of time suspected patients need to be isolated and save thousands of dollars per patient.
The test, which uses automated reverse-transcription real-time PCR, expands the firm's menu of CLIA-waived tests for use in near-patient and point-of-care settings.
The portable, battery-operated system will be an interim solution for decentralized testing in places where power may be unreliable.
The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.
The company's Diagnostics business was up 14 percent, while its Life Sciences business grew 13 percent. The firm also closed its $2 billion buy of IDT last week.
The company will use a portion of the credit facility to fund its announced acquisition of Integrated DNA Technologies.
Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.
The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.
Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.
In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.